Market research
7WS.F Sawai Pharmaceutical Co., Ltd
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- 10.1
- Analyst target
- Not available
- Dividend yield
- 2.9%
- Beta
- 0.38
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 2B
- P/E ratio
- 10.1
- Analyst target
- Not available
- Dividend yield
- 2.9%
- Beta
- 0.38
About
About Sawai Pharmaceutical Co., Ltd
Sawai Pharmaceutical Co., Ltd., together with subsidiaries, manufactures, sells, imports, and exports pharmaceutical products in Japan and the United States. The company offers drugs in various formulations, including tablets, oral dispersing tablets, capsules, granules, injections, tapes, ophthalmic/nasal solutions, syrups, etc. in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, chemotherapeutics, vitamins, anti-cancer, etc. It serves hospitals, general practitioners, and dispensing pharmacies. Sawai Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 7WS.F discussion.
5 years, 5 months ago
Sawai Group Holdings Co., Ltd is currently in a long term uptrend where the price is trading 2.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.
Sawai Group Holdings Co., Ltd's total revenue rose by 5.5% to $53B since the same quarter in the previous year.
Its net income has increased by 3.8% to $7B since the same quarter in the previous year.
Finally, its free cash flow fell by 44.8% to $-1B since the same quarter in the previous year.
Based on the above factors, Sawai Group Holdings Co., Ltd gets an overall score of 4/5.